Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach
- 17 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (15), 8088-8113
- https://doi.org/10.1021/acs.jmedchem.0c00279
Abstract
The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.Keywords
Funding Information
- Novartis Institutes for Biomedical Research Inc.
This publication has 55 references indexed in Scilit:
- Congenital Factor XI Deficiency: An UpdateSeminars in Thrombosis and Hemostasis, 2013
- National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011Circulation: Cardiovascular Quality and Outcomes, 2012
- Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysisBioorganic & Medicinal Chemistry Letters, 2009
- Protease‐Directed Drug DiscoveryPublished by Wiley ,2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- The role of molecular size in ligand efficiencyBioorganic & Medicinal Chemistry Letters, 2007
- The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complexBioorganic & Medicinal Chemistry Letters, 2005
- Interaction with the S1β-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2004
- Interaction with the S1$beta;-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2004